ATE304353T1 - Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff - Google Patents

Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff

Info

Publication number
ATE304353T1
ATE304353T1 AT02745358T AT02745358T ATE304353T1 AT E304353 T1 ATE304353 T1 AT E304353T1 AT 02745358 T AT02745358 T AT 02745358T AT 02745358 T AT02745358 T AT 02745358T AT E304353 T1 ATE304353 T1 AT E304353T1
Authority
AT
Austria
Prior art keywords
inhibitor
combination containing
antiepileptic
active
antiepileptic active
Prior art date
Application number
AT02745358T
Other languages
English (en)
Inventor
Wolfgang Loescher
Heidrun Potschka
Markus Schmutz
Original Assignee
Novartis Pharma Gmbh
Wolfgang Loescher
Heidrun Potschka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh, Wolfgang Loescher, Heidrun Potschka filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE304353T1 publication Critical patent/ATE304353T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02745358T 2001-06-05 2002-06-04 Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff ATE304353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0113663.9A GB0113663D0 (en) 2001-06-05 2001-06-05 Use of organic compounds
PCT/EP2002/006140 WO2002098418A1 (en) 2001-06-05 2002-06-04 Combination comprising a p-gp inhibitor and an anti-epileptic drug

Publications (1)

Publication Number Publication Date
ATE304353T1 true ATE304353T1 (de) 2005-09-15

Family

ID=9915953

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745358T ATE304353T1 (de) 2001-06-05 2002-06-04 Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff

Country Status (11)

Country Link
US (2) US20040180816A1 (de)
EP (1) EP1399157B1 (de)
JP (1) JP2004536076A (de)
CN (1) CN1617719A (de)
AT (1) ATE304353T1 (de)
BR (1) BR0209648A (de)
CA (1) CA2446160A1 (de)
DE (1) DE60206169T2 (de)
ES (1) ES2247352T3 (de)
GB (1) GB0113663D0 (de)
WO (1) WO2002098418A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
PE20060416A1 (es) * 2004-08-03 2006-06-09 Novartis Ag Composicion de inhibidores de renina e inhibidores de proteinas de efusion
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
EP2066323A2 (de) * 2006-09-12 2009-06-10 NeuroSearch AS Pharmazeutische zusammensetzungen mit kombinationen aus einer antagonistischen ampa-/kainat-verbindung und einem hemmer eines multdrug-resistenzproteins
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9504656B2 (en) 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059558T3 (es) * 1987-06-17 1994-11-16 Sandoz Ag Ciclosporins y su uso como productos farmaceuticos.
DE3832362A1 (de) * 1988-09-23 1990-03-29 Sandoz Ag Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
JPH08127541A (ja) * 1994-10-31 1996-05-21 Chugai Pharmaceut Co Ltd 新規制癌剤
GB9721352D0 (en) * 1997-10-08 1997-12-10 Medinnova Sf Resistance modifying agent

Also Published As

Publication number Publication date
US20040180816A1 (en) 2004-09-16
HK1064278A1 (en) 2005-01-28
CN1617719A (zh) 2005-05-18
WO2002098418A1 (en) 2002-12-12
DE60206169T2 (de) 2006-06-08
BR0209648A (pt) 2004-07-06
CA2446160A1 (en) 2002-12-12
DE60206169D1 (de) 2005-10-20
GB0113663D0 (en) 2001-07-25
ES2247352T3 (es) 2006-03-01
EP1399157B1 (de) 2005-09-14
US20070142266A1 (en) 2007-06-21
JP2004536076A (ja) 2004-12-02
EP1399157A1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
DE60331236D1 (de) Orale zusammensetzungen zur behandlung von diabetes
MA31822B1 (fr) Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
GB0012362D0 (en) Chemical compounds
NO20034782L (no) Farmasöytisk aktive uridinestere
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
EP1385508A4 (de) Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes
MA28182A1 (fr) Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues
BR0210139A (pt) Composições farmacêuticas
WO2003106381A3 (en) Human adam-10 inhibitors
DE60206169D1 (de) Kombination enthaltend einen p-gp hemmer und einen antiepileptischen wirkstoff
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ATE506959T1 (de) Verwendung von il-18 inhibitoren
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0315139A (pt) Agentes antibacterianos de tetraidroquinolina tricìclica
NO20076405L (no) Anvendelse av 24-nor-UDCA
YU82602A (sh) Korišćenje il-18 inhibitora za lečenje i/ili prevenciju ateroskleroze
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
EA200301187A1 (ru) Применение азитромицина для производства лекарственного средства для лечения неинфекционных воспалительных заболеваний
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite
PT1368016E (pt) Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
TW200719903A (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1399157

Country of ref document: EP

REN Ceased due to non-payment of the annual fee